Abstract
Long-term evidence supports a clustering of cardiovascular events in the early morning. Several studies have shown that platelet hyperreactivity to various stimuli is also present at this period of the day. However, the idea of treatment strategies reflecting the circadian variation in platelet reactivity has been largely neglected so far, and this is true despite the huge number of patients being treated with these drugs. Some pharmacodynamic data suggest that early-morning platelet hyper-reactivity may be overcome by shifting aspirin intake to the bedtime. However, there is lack of evidence whether shifting the time of intake or splitting the daily dose of P2Y12-inhibitors with a regular QD dosing (clopidogrel or prasugrel) to the evening would be effective to overcome platelet hyper-reactivity or to suppress the excess of cardiovascular events observed during morning hours. Further research is warranted to clarify whether such a simple and costless effort like dose shifting or splitting may be beneficial to prevent cardiovascular events.
| Original language | English |
|---|---|
| Pages (from-to) | 3-6 |
| Number of pages | 4 |
| Journal | Thrombosis and Haemostasis |
| Volume | 115 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2016 |
Fingerprint
Keywords
- ADP receptors
- Antiplatelet agents
- Antiplatelet drugs
- Clinical trials
- Platelet pharmacology
ASJC Scopus subject areas
- Hematology
Cite this
Prevention of cardiovascular events with antiplatelet treatment : Does time of intake matter for aspirin and ADP receptor blockers? / Sibbing, Dirk; Gross, Lisa; Aradi, D.
In: Thrombosis and Haemostasis, Vol. 115, No. 1, 2016, p. 3-6.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prevention of cardiovascular events with antiplatelet treatment
T2 - Does time of intake matter for aspirin and ADP receptor blockers?
AU - Sibbing, Dirk
AU - Gross, Lisa
AU - Aradi, D.
PY - 2016
Y1 - 2016
N2 - Long-term evidence supports a clustering of cardiovascular events in the early morning. Several studies have shown that platelet hyperreactivity to various stimuli is also present at this period of the day. However, the idea of treatment strategies reflecting the circadian variation in platelet reactivity has been largely neglected so far, and this is true despite the huge number of patients being treated with these drugs. Some pharmacodynamic data suggest that early-morning platelet hyper-reactivity may be overcome by shifting aspirin intake to the bedtime. However, there is lack of evidence whether shifting the time of intake or splitting the daily dose of P2Y12-inhibitors with a regular QD dosing (clopidogrel or prasugrel) to the evening would be effective to overcome platelet hyper-reactivity or to suppress the excess of cardiovascular events observed during morning hours. Further research is warranted to clarify whether such a simple and costless effort like dose shifting or splitting may be beneficial to prevent cardiovascular events.
AB - Long-term evidence supports a clustering of cardiovascular events in the early morning. Several studies have shown that platelet hyperreactivity to various stimuli is also present at this period of the day. However, the idea of treatment strategies reflecting the circadian variation in platelet reactivity has been largely neglected so far, and this is true despite the huge number of patients being treated with these drugs. Some pharmacodynamic data suggest that early-morning platelet hyper-reactivity may be overcome by shifting aspirin intake to the bedtime. However, there is lack of evidence whether shifting the time of intake or splitting the daily dose of P2Y12-inhibitors with a regular QD dosing (clopidogrel or prasugrel) to the evening would be effective to overcome platelet hyper-reactivity or to suppress the excess of cardiovascular events observed during morning hours. Further research is warranted to clarify whether such a simple and costless effort like dose shifting or splitting may be beneficial to prevent cardiovascular events.
KW - ADP receptors
KW - Antiplatelet agents
KW - Antiplatelet drugs
KW - Clinical trials
KW - Platelet pharmacology
UR - http://www.scopus.com/inward/record.url?scp=84951311209&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84951311209&partnerID=8YFLogxK
U2 - 10.1160/TH15-05-0430
DO - 10.1160/TH15-05-0430
M3 - Article
C2 - 26334227
AN - SCOPUS:84951311209
VL - 115
SP - 3
EP - 6
JO - Thrombosis and Haemostasis
JF - Thrombosis and Haemostasis
SN - 0340-6245
IS - 1
ER -